Journal Article

FTY720 combined with tacrolimus in <i>de novo</i> renal transplantation: 1-year, multicenter, open-label randomized study

Andries J. Hoitsma, Ervin S. Woodle, Daniel Abramowicz, Pieter Proot and Yves Vanrenterghem

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 26, issue 11, pages 3802-3805
Published in print November 2011 | ISSN: 0931-0509
Published online September 2011 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfr503
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study

Show Summary Details

Preview

Background. FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine.

Methods. This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation.

Results. Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm.

Conclusion. FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.

Keywords: FTY720; mycophenolate mofetil; renal transplantation; sphingosine 1-phosphate receptor; tacrolimus

Journal Article.  1683 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.